Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences, Inc. (CTKB) received a notice that officer Philippe Busque intends to sell 31,666 shares of common stock under Rule 144, with sales to be executed through Morgan Stanley Smith Barney LLC. The shares relate to a stock option exercise dated September 2, 2026. As context, common stock outstanding is listed as 129,983,253 shares as of September 2, 2026.
Cytek Biosciences, Inc. (CTKB) reported that a jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement case brought by Beckman Coulter, Inc. The jury decided in Cytek’s favor on three of the four asserted patent claims, finding both noninfringement and invalidity for those three claims.
For the remaining claim, the jury found no literal infringement but did find infringement under the doctrine of equivalents, and awarded past damages of $20 million in lost profits and $36.11 million in royalties. Cytek stated that the verdict does not require any changes to its current product offerings or operations, and its spectral flow cytometry products remain available globally.
Cytek intends to file post-verdict motions challenging the doctrine-of-equivalents finding and the associated damages, and may pursue other post-trial remedies, including a possible appeal to the U.S. Court of Appeals for the Federal Circuit. The company also highlighted that additional costs, potential injunctive relief, or ongoing royalty obligations could result from further legal proceedings.
Cytek Biosciences, Inc. (CTKB) reported that President and CEO Wenbin Jiang exercised Restricted Stock Units into common stock on August 18, 2026. Four RSU vesting events resulted in the issuance of 120,095 shares of common stock. To cover related tax withholding obligations, 36,269 shares of common stock were withheld and surrendered at $4.67 per share. The RSU awards vest over four-year schedules with specified portions vesting each May 18, August 18, November 18, and March 10.
Cytek Biosciences, Inc. (CTKB) reported that Chief Financial Officer William D. McCombe exercised restricted stock units (RSUs) into 35,420 shares of common stock on August 18, 2026, through three RSU awards. In connection with these vestings, 11,904 shares of common stock were withheld and surrendered to Cytek to satisfy tax withholding obligations at a price of $4.67 per share. Each RSU represents a contingent right to receive one share of common stock, and the related awards vest over four years in specified installment schedules tied to May 18, August 18, November 18 and March 10 of various years.
Cytek Biosciences, Inc. (CTKB) director Glenn P. Muir reported an automatic conversion of 3,086 Restricted Stock Units into 3,086 shares of Common Stock on August 18, 2026. The RSU conversion price was $0.00 per share.
Following this transaction, Muir’s directly held RSU balance tied to this award is reported as 52,469 units, and his directly held Common Stock position from this transaction is 3,086 shares3 years in multiple tranches, including 2/36 of the total shares vesting on August 18, 2026, and additional 3/36 and 4/36 installments on specified dates thereafter, as long as the vesting conditions are met.
Cytek Biosciences, Inc. (CTKB) reported that director Michael Holder exercised restricted stock units into common stock. On August 18, 2026, 2,181 Restricted Stock Units converted into 2,181 shares of common stock, increasing his directly held common shares to 62,875 and reducing his Restricted Stock Units to 7,276. Each RSU represents a contingent right to receive one share of common stock, with the underlying RSU award vesting in scheduled tranches through at least August 18, 2025 as described in the vesting footnote.
Cytek Biosciences, Inc. (CTKB) director Richard Chin reported an exercise and conversion of 6,107 Restricted Stock Units (RSUs) into 6,107 shares of Common Stock on August 18, 2026. Following this transaction, he directly held 28,499 shares of Common Stock and 44,790 RSUs. Each RSU represents a contingent right to receive one share of common stock, with the RSU award vesting in scheduled tranches between August 18, 2025 and August 18, 2026.
Cytek Biosciences, Inc. (CTKB) reported that director and Chief Technology Officer Yan Ming had several Restricted Stock Unit ("RSU Award") tranches vest on August 18, 2026, each RSU converting into one share of common stock. In total, 33,270 shares of common stock were acquired through exercises or conversions of RSUs. To cover related tax obligations, 8,088 shares of common stock were withheld and surrendered to Cytek at $4.67 per share. The RSU Awards vest over four-year schedules, with specified fractions of the total shares vesting on May 18, August 18, November 18, and March 10 of each year for the different grants.
Cytek Biosciences, Inc. granted Chief Legal Officer and Secretary Ilan Feuchtwang new equity awards. The awards consist of 241,416 Restricted Stock Units, each representing one share of common stock, and an option for 127,118 shares of common stock at an exercise price of $4.66 per share, expiring on August 9, 2036. The RSUs and options vest over four years under specified installment schedules, in each case subject to the executive’s Continuous Service under the company’s 2021 Equity Incentive Plan.
Cytek Biosciences, Inc. received an amended Schedule 13G/A disclosing significant ownership positions by Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 7,162,923 shares of common stock, representing 5.5% of the class, all with shared voting and dispositive power. Millennium Management LLC, Millennium Group Management LLC, and Mr. Englander each report beneficial ownership of 9,338,010 shares, or 7.2% of the class, also solely through shared voting and dispositive power. The filing explains that the securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and it includes language that this structure should not, by itself, be construed as an admission of beneficial ownership by these reporting persons.